This HTML5 document contains 84 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n23http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n15http://linked.opendata.cz/resource/drugbank/company/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00436/identifier/chemspider/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00436/identifier/chebi/
n4http://linked.opendata.cz/resource/drugbank/mixture/
n14http://bio2rdf.org/drugbank:
n25http://linked.opendata.cz/resource/drugbank/drug/DB00436/identifier/wikipedia/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00436/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00436/identifier/kegg-compound/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00436/identifier/pubchem-compound/
n24http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n22http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00436/identifier/pubchem-substance/
n27http://www.drugs.com/cdi/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00436/identifier/kegg-drug/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00436/identifier/drugbank/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00436/identifier/national-drug-code-directory/
n6http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00436
rdf:type
n3:Drug
n3:description
A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810)
n3:group
approved
n3:halfLife
8.5 hours
n3:indication
For the treatment of high blood pressure and management of edema related to heart failure.
n3:manufacturer
n15:271B4DFE-363D-11E5-9242-09173F13E4C5
owl:sameAs
n14:DB00436 n24:DB00436
dcterms:title
Bendroflumethiazide
adms:identifier
n9:PA448563 n10:2315 n11:D00650 n12:0003-0606-50 n16:46508672 n17:3013 n19:C07758 n20:2225 n21:DB00436 n25:Bendroflumethiazide
n3:mechanismOfAction
As a diuretic, bendroflumethiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like bendroflumethiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of bendroflumethiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.
n3:packager
n15:271B4DFC-363D-11E5-9242-09173F13E4C5 n15:271B4DFD-363D-11E5-9242-09173F13E4C5 n15:271B4DFA-363D-11E5-9242-09173F13E4C5 n15:271B4DFB-363D-11E5-9242-09173F13E4C5
n3:synonym
Bendrofluazide Bendroflumetiazida 6-Trifluoromethyl-3-benzyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide Bendroflumethiazidum Bendroflumethiazid +--3-Benzyl-3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide Benzhydroflumethiazide Bendrofluméthiazide
n3:foodInteraction
Take with food to increase bioavailability.
n3:mixture
n4:271B4DF5-363D-11E5-9242-09173F13E4C5 n4:271B4DF6-363D-11E5-9242-09173F13E4C5 n4:271B4DF4-363D-11E5-9242-09173F13E4C5 n4:271B4DF9-363D-11E5-9242-09173F13E4C5 n4:271B4DF7-363D-11E5-9242-09173F13E4C5 n4:271B4DF8-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
96%
n3:synthesisReference
Goldberg, M.; U.S. Patent 3,265,573; August 9, 1966; assigned to E.R. Squibb & Sons, Inc. Lund, F., Lyngby, K. and Godtfredsen, W.O.; U.S. Patent 3,392,168; July 9, 1968; assigned to Lovens Kemiske Fabrik ved A. Kongsted, Denmark.
n22:hasConcept
n23:M0002310
foaf:page
n27:bendroflumethiazide.html
n3:IUPAC-Name
n5:271B4E08-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B4E0E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B4E0D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B4E0A-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B4E0B-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B4E0C-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B4E1E-363D-11E5-9242-09173F13E4C5 n5:271B4E06-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B4E20-363D-11E5-9242-09173F13E4C5 n5:271B4E04-363D-11E5-9242-09173F13E4C5 n5:271B4E07-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B4E21-363D-11E5-9242-09173F13E4C5 n5:271B4E05-363D-11E5-9242-09173F13E4C5
n3:pKa
n5:271B4E22-363D-11E5-9242-09173F13E4C5
n6:hasATCCode
n7:C03AA01
n3:H-Bond-Acceptor-Count
n5:271B4E14-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B4E15-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B4E0F-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B4E10-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B4E12-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B4E11-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B4E13-363D-11E5-9242-09173F13E4C5
n3:absorption
Absorbed relatively rapidly after oral administration
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
73-48-3
n3:category
n3:containedIn
n18:271B4E03-363D-11E5-9242-09173F13E4C5 n18:271B4E01-363D-11E5-9242-09173F13E4C5 n18:271B4E02-363D-11E5-9242-09173F13E4C5 n18:271B4DFF-363D-11E5-9242-09173F13E4C5 n18:271B4E00-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B4E1A-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B4E1C-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B4E1D-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B4E1F-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B4E19-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B4E18-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B4E1B-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B4E09-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B4E16-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B4E17-363D-11E5-9242-09173F13E4C5